UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2007
Commission File Number 000-22286
Taro Pharmaceutical Industries Ltd.
(Translation of registrant's name into English)
14 Hakitor Street, Haifa Bay 26110, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F. Form 20-F |X| Form 40-F |_|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes |_| No |X|
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_____.
Taro to Reschedule Shareholders Meeting on Proposed Merger with
Sun Following the Availability of Financial Results
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 16, 2007--Taro
Pharmaceutical Industries Ltd. ("Taro," the "Company," Pink Sheets:
TAROF) today announced that it will reschedule its shareholders
meeting, previously scheduled for September 25, 2007, on the proposed
merger with Sun Pharmaceutical Industries Ltd. ("Sun," Reuters:
SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715), to a time
following the availability of financial results for the year ended
December 31, 2006 and for the first and second quarters of 2007.
The Company noted that a number of its shareholders have requested
updated financial information in conjunction with their consideration
of the proposed merger with Sun. Taro has decided to defer the
shareholders meeting pending the availability of these financial
statements or a detailed update on current financial results. At this
time the Company hopes that audited financial statements for 2006 and
unaudited financial statements for the first two quarters of 2007 will
be available in September and that the shareholders meeting can be
rescheduled for late October or November. Taro will set a new record
date for the upcoming meeting and will mail supplemental proxy
materials to its shareholders.
About Taro and Sun
Taro is a multinational, science-based pharmaceutical company,
dedicated to meeting the needs of its customers through the discovery,
development, manufacturing and marketing of the highest quality
healthcare products. For further information on Taro Pharmaceutical
Industries Ltd., please visit the Company's website at www.taro.com.
Established in 1983, listed since 1994 and headquartered in India,
Sun Pharmaceutical Industries Ltd. is an international, integrated
specialty pharmaceutical company. It manufactures and markets a large
basket of pharmaceutical formulations as branded generics as well as
generics in India, the U.S., and several other markets across the
world.
SAFE HARBOR STATEMENT
Certain statements in this release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements
that do not describe historical facts and statements that refer or
relate to events or circumstances the Company "hopes," "intends," or
"expects" to happen, or similar language, and statements with respect
to the availability of financial information and the shareholders
meeting on the transaction with Sun described in this press release.
Although Taro Pharmaceutical Industries Ltd. believes the expectations
reflected in such forward-looking statements to be based on reasonable
assumptions, it can give no assurances that its expectations will be
attained. Factors that could cause actual results to differ include
the possible unavailability of financial information, the inability to
conduct a shareholders meeting on the transaction with Sun, actions of
the Company's lenders, creditors and Sun, general domestic and
international economic conditions, industry and market conditions,
changes in the Company's financial position, litigation brought by any
party in any court in Israel, the United States, or any country in
which Taro or Sun operates, litigation, regulatory actions and
legislative actions in the countries in which Taro or Sun operates,
and other risks detailed from time to time in the Company's SEC
reports, including its Annual Reports on Form 20-F. Forward-looking
statements speak only as of the date on which they are made. The
Company undertakes no obligations to update, change or revise any
forward-looking statement, whether as a result of new information,
additional or subsequent developments or otherwise.
CONTACT: Taro Pharmaceutical Industries Ltd.
Daniel Saks, 914-345-9000 ext. 6208
Vice President, Corporate Affairs
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: August 16, 2007
TARO PHARMACEUTICAL INDUSTRIES LTD.
By: /s/ Tal Levitt
--------------
Name: Tal Levitt
Title: Director and Secretary